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Protein kinases are involved in many essential cellular processes, and are regulated 
in a dynamic manner by the movement of domains or motifs via interaction with 
various proteins and substrates.  Protein kinase deregulation can lead to a variety of 
diseases, including cancer and diabetes. Protein kinase A (PKA) has been a prototype 
to study the entire family, including for studies in drug discovery research. However, 
the high sequence similarities in the kinase domain of protein kinases hinders the 
development of target-specific inhibitors, and the use of PKA alone is insufficient. 
Mutants of PKA can act as surrogate targets to aid the design of target specificity. In 
this work, we use a combination of several biophysical methods to investigate the 
properties of PKA, PKA based surrogate kinases (PKAB3 & PKA-Au6), the cancer target 
Aurora kinase, including especially their interactions with inhibitors. We characterized 
a series of 32 enantiomerically pure inhibitors with respect to interactions with 
protein kinase A (PKA) and its mutant PKAB3 as a PKB surrogate. The ligands bind to 
the hinge region, ribose pocket, while their substituted aromatic rings (phenyl, thienyl) 
bind to the glycine-rich loop at the ATP site. Biological assays show their high potency 
against both PKA and PKAB3, generally with preference to PKA. The crystal structures 
reveal a multi-facetted network of ligand–glycine-rich loop interactions, with efficient 
water replacement contributing to the binding strength. Site-directed mutagenesis 
and biophysical characterization of the glycine–rich loop mutants (T51G and G55A-
PKA) show weakened affinities against tested inhibitors: 1i, 1p, 1c and H-89. We also 
show structural effects of the aromatic residue phenylalanine that is highly conserved 
among the AGC kinase group, corresponding to Phe327 in PKA, and its role in inhibitor 
binding. The inhibitor-Phe327 interactions reveal a complex mix of favorable and 
unfavorable contacts: Phe327 can block inhibitors from occupying the ATP-binding 
pocket, but may also be displaced to enable tight binding. The PKA-based Aurora 
kinase B (PKA-AU6) model, which shares this Phe327, provides examples of crystal 
structures (PDB ID: 5N23) showing effects on the binding affinities of the pan-Aurora 
iii 
 
inhibitor AT9283, and also the novel tricyclic dianilino-pyrimidine inhibitors (1B & 2A). 
The pan-kinome inhibitor staurosporine is known to be able to displace Phe327.  We 
also observe how bisubstrate inhibitors can be used for studies of strong protein 
peptide-interactions. In summary, this work advances the understanding of how 
subtle aspects of flexibility, water structure, and chemical interactions determine 
inhibitor binding kinetics and energetics. Such detailed understanding is required for 
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Protein phosphorylation plays a central role in biological processes. Almost every 
cellular event is regulated in part through protein phosphorylation which is 
responsible for modulating biological activity and controlling localization in the cells 
[1]. The fascination of the discovery of protein phosphorylation was in recognizing 
how information about an external signal could be transferred to the correct 
intracellular recipient by a clearly defined chemical process. By doing this across a 
wide range of signals and cellular components, phosphorylation orchestrates the 
cellular activities for total harmonious function. Phosphorylation of proteins is carried 
out by protein kinases which transfer terminal phosphate of ATP to the substrates or 
















Figure 1.1: Protein kinases carry out phosphorylation using a mechanism whereby ATP first binds to 
the active site of the enzyme, followed by substrate binding. The kinase phosphorylates the substrate 
by transferring the terminal phosphate from ATP to the substrate. The figure is adapted with 





There are nine amino acids which can be phosphorylated, using either ATP, GTP or 
PEP as a phosphate donor, under physiological conditions [3]. The phosphorylation 
of different amino acids is typically carried out by different protein kinases. Thus, 
serine/threonine kinase responsible for serine/threonine phosphorylation and 
tyrosine kinase for tyrosine residues. Phospho-threonine and serine residues are 
more abundant than phospho-tyrosine [4]. Although most commonly studied event 
of the cell signaling processes is protein phosphorylation, much information 
regarding these processes remains unknown. About 30% of cellular proteins are 
estimated to be phosphorylated, and the human genome encodes more than 500 
protein kinases [5, 6].  
1.1.2. Brief history of protein phosphorylation 
The activity of protein kinase was first described by George Burnett and Eugene P. 
Kennedy in 1954 during their work on rat liver mitochondria. They found that casein 
protein is phosphorylated by mitochondrial enzyme [7]. In 1956, Krebs and Fischer 
observed that the phosphorylase enzyme catalyzes glycogen breakdown, is 
phosphorylated by phosphorylase kinase, and dephosphorylated by another enzyme 
called phosphorylase phosphatase [8]. Protein phosphorylation studies increased 
significantly after the discovery of cyclic AMP-dependent protein kinase (PKA) by 
Walsh, Perkins, and Krebs, in 1968, which provide clues that it can phosphorylate 
more than one protein [9]. Calcium-dependent protein kinase activity was observed 
in rat brain, attributed to diacylglycerol activated protein kinase C activity [10, 11] . In 
1991, Sir Philip Cohen discovered that glycogen synthase is phosphorylated at nine 
serine residues by different kinases [12]. The protein v-src is encoded by the 
transforming gene of Rous sarcoma virus. In the late 1970s, Ray Erikson discovered 
that v-src is a kinase which phosphorylates tyrosine residues [4, 13] and can act as an 
oncogene. The discovery of JAK kinases led to expanded interest in signaling 
pathways. The discovery of MAP kinase in the 1986 by Ray and Sturgill added more 
information regarding protein kinase cascade. They discovered insulin dependent 
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activation of a serine threonine kinase that phosphorylated microtubule-associated 
protein-2 (MAP2) [14]. With the discovery that therapeutic inhibition of protein 
kinases is a viable approach, research into protein kinases and their inhibitors has 
increased dramatically over the last few decades. 
1.2. Summary of kinases in focus for this thesis 
1.2.1. Protein kinase A 
PKA has long been a prototype for general studies on protein kinases. The activity of 
PKA, also known as cAMP-dependent protein kinase, or phosphorylase kinase kinase, 
is dependent on the level of cAMP [9]. cAMP binding dissociates the regulatory 
subunit from an inactive tetrameric PKA, releasing the active catalytic subunit. The 
active enzyme catalytic domain has been used as a research and structural model for 
studies of a broad range of kinase properties, including regulatory mechanisms, 
recognition of substrate and binding, phosphoryl transfer mechanism, in part 
because of well established bacterial expression protocols and reproducible 
crystallizability [15, 16].  
1.2.1.1. Structure of protein kinase A 
In the early 1990s, the first ternary complex of the catalytic subunit of PKA with a 
pseudosubstrate inhibitor peptide, PKI (5-24) (TTYADFIASGRTGRRNAIHD) in the 
presence of the MgATP analogue MnAMP-PNP was solved, at resolutions around 2.0 
Å [16-18]. The full length PKI inhibitor, heat stable up to 90° C, contains at its amino 
terminus (5-24) the kinase inhibitory domain [19, 20].  In the presence of MgATP, it has 
a very high affinity towards PKA (with a Ki of approximately 2nM)  [21, 22]. PKA is a 
tetramer holoenzyme which contains a regulatory (R) homodimer subunit and two 
catalytic (C) subunits in the inactivated physiological state [18].  The enzyme consists 
of two lobes, the N-terminal lobe is quite flexible, consisting mostly of beta-sheets. 
The C-terminal lobe is mostly helical and contains a segment for activation that often 
includes residues whose phosphorylation activates the kinase. The two lobes are 
connected by a polypeptide segment called the hinge. A cleft between the two lobes 
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forms the ATP binding pocket and contains the catalytic residues [16, 18, 23] (Figure 
1.2). 
The N-terminal lobe has five anti-parallel beta stands and an alpha helix which is 
located between the β3 and β4 strands. The N-lobe is also primarily responsible for 
nucleotide binding, as most of the interactions with MgATP involve this lobe. There is 
a consensus sequence of GxGxxGxV in the N-lobe, called the glycine-rich loop (in PKA 
numbering: Gly50-x-Gly52-x-x-Gly55-x-Val57), which covers the nucleotide. In 
contrast, the C-lobe contains seven α-helices and, compared to the conserved protein 
kinase core, has an additional C-terminal extension. This domain contains the 
substrate recognition elements and catalytic residues. The hinge region (residues 


















Figure 1.2: The catalytic subunit of PKA as a prototype for AGC kinases. The 
N-lobe and C-lobe joined by hinge (grey), ATP (red) binds in the pocket 
formed by N and C-lobe under the glycine-rich loop (dark yellow). The DFG, 
HRD, activation segment and Helix C show as dark magenta, cyan, green 
and dark yellow, respectively. 
5 
 
A lysine residue (Lys72) from the β3 strand of the N-lobe coordinates the α- and β- 
phosphates of the ATP molecule, but is unable to make contacts with the γ-phosphate 
without the movement of β-strands [16]. Biochemical data also shows the critical role 
of this lysine residue in recognition of phosphates [24, 25], and it is often mutated to 
create “kinase dead” mutants as a control for activity studies. 
As mentioned above, the C-lobe, large compared to N-lobe, is primarily α-helical and 
is associated mostly with peptide binding and catalysis.  The helices (from αD-αI) are 
conserved in eukaryotic protein kinases (EPKs) [26]. In PKA, helices E and F are 
hydrophobic, connected by a β-structure at their surface. The catalytic loop 
connected by the β- strand 6 and 7. The activation segment of PKA starts with widely 
known conserved motif called DFG motif (Asp184-Phe185-Gly186) and end of αF 
helix. The DFG motif is present between β strands 8 and 9 [27] . The role of Asp184 
of DFG is to bind to the Mg ion, which coordinates the β and γ-phosphate [16]. The 
activation segment contains Thr197 which appears to be autophosphorylated and 
important for kinase activity. This phosphorylation also observed in recombinant 
mouse enzyme [16, 18, 28]. 
1.2.1.2. Function and Regulation 
Protein kinases are modular proteins whose activities are modulated dynamically by 
chemical modification (especially phosphorylation, but also e.g. the attachment of 
membrane binding tethers), intra- and intermolecular complex formation, including 
attachment to scaffolding proteins. PKA is ubiquitously expressed and regulates key 
biological processes in differentiation and proliferation of the cell, metabolism and 
memory formation [29, 30]. Like protein kinases in general, the regulation of PKA also 
includes associated with their interacting proteins, domains and  transient movement 
of motif or linker [31]. 
The cAMP-dependent PKA is a tetramer complex composed of two regulatory and two 
catalytic subunits in mammalian cells. The holoenzyme—the inactive state—exists 
when there are low levels of cAMP (Figure 1.3). Above a threshold concentration of 
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cAMP in cells, cAMP binding to the regulatory subunit releases the catalytic subunit 
which is then active and carries out its function of protein phosphorylation [32, 33]. 
Thus, the regulatory subunit acts as a docking site for the cAMP. Additionally, the 
holoenzyme (two regulatory with two catalytic subunits) plays a role in cell localization. 
Usually, the holoenzyme present in cytoplasm but when regulatory subunits are 
released, the catalytic subunit is moved to the nucleus [34-36]. There are three 
isoforms (Cα, Cβ and Cγ) for catalytic subunit and four isoforms of the regulatory 
















Figure 1.3: Protein Kinase A activated through the external signal via cAMP. a). PKA has a function in 
cytoplasm and nucleus. The catalytic subunit is released from regulatory part due to the abundance 
of cAMP in cells and the kinase ultimately acts in the biological event by phosphorylation. b). The 
catalytic and regulatory subunit has three (Cα, Cβ, and Cγ) and four isoforms (RIα, RIβ, RIIα, and RIIβ). 





The Protein Kinase A (PKA) has been widely used as a model for the understanding of 
cellular signaling mechanisms. As activation of PKA depends on the external signal 
(cAMP), and its total spectrum of activity depends on other proteins and in turn their 
phosphorylation or other translational modification states, fine tuning of PKA and 
substrates is pivotal to maintain signaling process fidelity and robustness. The first 
substrates of PKA were identified in 1980 and the number of known sites has 
increased dramatically since. So far, more than 100 PKA substrates have been 
identified. PKA phosphorylation consensus sequences have been described as Arg-
Arg-X-Ser/Thr (RRX [S/T]), Arg/Lys-X-X-Ser/Thr ([R/K] XX[S/T]), and Arg/Lys-X-
Ser/Thr([R/K] X [S/T]) [37]. 
1.2.2. Protein kinase B 
Protein kinase B (PKB, also known as AKT) is a serine /threonine kinase which is a 
central enzyme in several intracellular signaling pathways. PKB has a major role in the 
PI3K pathway and responds to various type of signals. These responses include 
phosphorylation of a wide range of proteins involved in cell growth, survival, 
proliferation, and regulation of metabolism [38, 39]. Three PKB/AKT isoforms have 
been found identified, known as PKBα, PKBβ and PKBγ, respectively (also known as 
AKT1, AKT2 and AKT3). All PKB isoforms show similar domain structures and almost 
80% sequence identity, but differ with respect to gene location (on chromosomes (14, 
19, and 1) [40-44]. The function of PKB isoforms appear to be specific for survival, 
growth and metabolism, depending on the stimulus or localization [45]. PKBα is 
necessary for trophoblast differentiation and regulates and maintenance placental 
development, PKBβ plays roles in animal growth, angiogenesis, β-cell function and 
glucose metabolism and PKBγ help in brain development  [46-49]. 
1.2.2.1. Protein kinase B /AKT and PI3K signaling pathway 
The phosphatidylinositol 3-kinases (PI3K)/PKB pathway is a master regulator of 
various cellular response and plays a pivotal role in the growth, development, and 
metabolism. The PI3-kinase regulates different protein kinases upon phosphorylation 
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and induces an array of responses. Receptor tyrosine kinases (RTK) are 
autophosphorylated by G-protein coupled receptors and binding to e.g. insulin or 
growth factors or integrin, and then activate PI3 kinase (Figure 1.4).  The PI3-kinase 
generates the second messenger lipid product PtdIns(3,4,5)P3 from PtdIns(4,5)P2, 
and PKB interacts with the PtdIns(3,4,5)P3 via its PH domain, and is thereby 
translocated to the plasma membrane from the cytoplasm.  It is believed that binding 
of PtdIns(3,4,5)P3 induces a conformational change in PKB upon which kinases 
phosphoinositide-dependent kinase1and 2 (PDK1 and PDK2) phosphorylate Thr308 
and Ser473 residues of PKB [38, 50-55] . Deregulation of PKB by mutation or 
overexpression has been found in many cancer types, including melanomas, breast, 
ovarian, lung and pancreatic [39, 56-58]. More than 60% PKB overexpression is 
observed in prostate tumor cells, and an approximately 50% increase of PKB activity 
is found in breast and prostate tumor cells [59-62]. All three isoforms of PKB are found 














Figure 1.4: PKB/AKT activation mechanism. Receptor tyrosine kinase (RTK) activates by ligand followed by 
phosphatidylinositol 3-kinase (PI3-kinase) to produce phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PH 
domain of PKB and PDk1 interact with PIP3. PKB becomes phosphorylated by PDK1 and S473-K and 




Protein kinase B, as a member of the AGC kinase group (PKA, PKC, PKC, PDK1, SGK, 
etc.), phosphorylates serine or threonine amino acid residues and share structural 
similarities with the rest of the group [64, 65]. More than 80% sequence identity are 
shared between PKBα, PKBβ and PKBγ [66] (Figure 1.5). All PKB isoforms share a 
conserved domain architecture, including a kinase domain, an N-terminal pleckstrin 
homology (PH) domain, and a C-terminal regulatory domain which contains the AGC 
kinase characteristic hydrophobic motif [67] (Figure 1.6). 
The N-terminal PH domain is well known as a modular domain, contains 
approximately 100 amino acids, and is present in over 200 gene encoding proteins 
[68, 69].  The PH domain was first discovered in platelet protein pleckstrin; later, Bruce 
J. Mayer and co-workers termed it the pleckstrin homology (PH) domain [69, 70]. The 
PH domain of PKB and PDK1 coordinates PIP3 in different orientations [67].  It 
provides the mechanism for PKB activation through interacting with PI3-kinase 
products and anchoring the PH domain-containing proteins to the membrane [71, 
72]. PI3-kinase signaling from platelet-derived growth factor (PDGF), epidermal 
growth factor (EGF) and basic fibroblast growth factor (bFGF) via PKB is dependent on 



































The similarities that the catalytic domain of PKB kinase shares with the rest of the AGC 
kinase family include its dependence on the phosphorylation of conserved thr308 
residues in the activation loop. The activation loop is defined between DFG and APE 
motifs [74, 75]. Along with the Thr308, there is another phosphorylation site present 
in the C-terminal strand of the kinase domain, at a segment known as a regulatory 
hydrophobic motif.  The consensus sequence is F-X-X-F/Y-S/T-Y/F (where X is any 
amino acid) and is common not only to all PKB isoforms but also to most other 
Figure 1.5: Multiple sequence alignment of PKB/AKT isoforms (AKT1, AKT2, and AKT3, 




members of the AGC kinase family.  For PKB, phosphorylation of Ser474 in the 
hydrophobic motif appears to be essential to acquire full kinase activity and the crystal 
structure of PKB shows that interactions with the phosphorylated segment order the 













PKA is a close homologue of PKB and their kinase domains and the ATP binding sites 
share approximately 45% and 80% sequence identity, respectively [79]. The α-
isoforms of PKA and PKB have only two residues that differ in their adenine-binding 
site; these are valine123 and veucine173 in PKA, corresponding to alanine and 
methionine, respectively, in PKB [80]. PKA has been used for the studies of ligand-
protein interactions, especially for anti-cancer drug design of PKB because of rapid 
and easy crystallization process, and difficulties of getting native PKB crystals. It has 
also provided additional features to study selectivity between PKA and PKB [79]. The 
crystal structure of PKAB2 (PKAα V123A, L173M) shows the side chain of Q181 residue 
close to the hinge region of ATP binding site which is distant in the native PKA crystal 
structure. An additional mutation in PKA (Q181K) corrected the model, as confirmed 
by the crystal structure of PKAB3 (PKAα V123A, L173M. Q181K) and surface plasmon 
resonance studies [80].   
Figure 1.6: The architecture of PKB/AKT isoforms. The kinase domain in the central region. The PH 
(pleckstrin homology) and hydrophobic motif (HM) is located at the N and C-terminal adjacent to the kinase 
domain. Phosphorylation sites are indicated as a blue circle. 
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The challenge of developing PKB inhibitors is to get not only selectivity and specificity 
among the three isoforms, but also against other protein kinases, as they share high 
sequence similarity in ATP binding pocket. Most of the tight binding inhibitors target 
the ATP site.  However, there are examples that show  inhibitors may be  based on 
additional or allosteric sites, providing specificity derived from PH domain 
interactions, for example, to thereby specifically block activation [81-83]. More than 
10 PKB inhibitors are in clinical testing stage, and approximately 5 inhibitors are in 
clinical phase 2.  
1.2.2.4. ATP Site targeting inhibitors 
Compounds developed in recent drug discovery programs include ATP-competitive 
PKB inhibitors based on chemical moieties azepane (balanol), aminofurazans 
(GSK690693), pyrazole (AT7867, AT13148) and thiophenecarbxamide derivatives 
(GSK2110183, GSK2141795) [84]. Afuresertib (GSK2110183) is a pan-PKB inhibitor 
which is in clinical phase 2. The inhibitor is orally administered, potent with Ki values 
of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively [85]. Afuresertib 
was developed using high throughput screening which identified a 2-pyrimidyl-5-
amidothiophene derivative which, based on structure-activity analyses and 
replacement of the pyrimidine with pyrazole, lead to the potent PKB inhibitor (Figure 
1.7). The replacement of thiophene ring with a furan ring in afuresertib resulted in 















Due to high similarity of the kinase sequence in the ATP binding site, and the difficulty 
of making quantitative predictions of binding energy, retrospective analyses of 
structure-activity relationships (SAR) and rational design are gaining in importance. 
Although many ATP-competitive PKB inhibitors are selective against other kinases, 
their selectivity among isoforms is usually not promising, as shown by the binding 
affinity of afuresertib. Therefore, the researchers have been trying to exploit non-
competitive ATP sites to develop more selective inhibitors. Wen-I Wu, et al., showed 
PH domain and inhibitor interactions by determining the inhibitor complex of the full 
length PKBα protein, which includes its PH domain. Their findings show a “PH-in” 
conformation which resulted in close contact between the kinase and PH domains 
away from membrane [87]. The MK2206 inhibitor also acted as a “PH-in” binder, 


















The cell cycle process is an sequence of events which occur during cell duplication, 
division and is tightly regulated through series of checkpoints. The cycle is typically 
described to start from G1 (Gap), and procede through S (Synthesis), G2 (Gap) and M 
(Mitosis and cytokinesis) phases (Figure 1.8). The G1 phase prepares everything for 
DNA synthesis and, together with S and G2, is known as interphase. The cell size 
increases at this phase. Prior to entering M phase, checkpoints of the G2 phase make 
sure that everything is prepared for continuation. Finally, the M phase is comprised of 
prophase, metaphase, anaphase, telophase and cytokinesis. In this phase, 
chromosomes are separated and distribute into two daughter cells. During these 


















Figure 1.8: Schematic representation of the cell cycle. The M phase stands 
for mitosis where chromosome separation and cytokinesis occurs. The G1 
and G2 phase indicates gap phase 1 and 2, respectively. The S phase 




Interplay between mitotic spindle assembly and disassembly is important for the 
reproduction of genome during cellular reproduction [89]. The Aurora kinases are 
serine-threonine kinases that regulate many of the processes during cell division. 
They are the key regulators of mitosis and are involved in controlling spindle function, 
chromosome condensation, orientation, chromatid segregation and cytokinesis [90]. 
Glover and co-workers first identified the Aurora gene during screening from a 
Drosophila melanogaster that was defective in spindle-pole function and named 
Aurora, an “exotic beauty of north pole region” [91]. The Aurora genes are also found 
in yeast (S.pombe, S.cerevisiae), Drosophila, C.elegans and Xenopus [92].   
The human has three Aurora isoforms, namely Aurora A, B, and C, respectively. 
Human Aurora A and Aurora B share 71 % sequence identity. Aurora kinases contain 
three domains: a conserved catalytic domain, a variable N-terminal domain (residues, 
39-129) which is varied in size and sequence, and a short segment of C-terminal (15-
20, residues).  Aurora kinases contain characteristic short amino acid motifs in the C-
terminal domain of the kinase called the D-box, an A-box in the N-terminal domain, 
and the activation loop in the kinase domain (Figure 1.9). Phosphorylation (Thr) of the 
activation loop of the aurora kinases is needed for  their kinase activity. Aurora kinases 
display their dynamic properties by interacting with different proteins, and by 
changing localization and function  [90, 93, 94]. In the following sections, only Aurora 

























Figure 1.9: Representation of human Aurora kinases. The catalytic, activation loop and D-box are 
colored with “light wheat”, “deep cyan”, and black, respectively. The phosphorylatable threonine 




The human Aurora kinases share very similar sequences in their catalytic domain but 
diverge in their functions and subcellular localizations (Figure 1.10). Aurora kinase A 
plays multiple roles in the cell division from G2 to M, including centrosome separation, 
maturation and spindle assembly [95]. Mutations in Aurora can lead to failure of 
chromosome separation and formed monopolar spindles in Drosophila [91]. The 
centrosome separation is facilitated by Aurora A which phosphorylates Eg5, a kinesin-
like motor protein [93]. At the end of S phase and at the beginning of the G1 phase, 
the presence of Aurora A in duplicated centrosomes was found by indirect 
immunofluorescence studies. Its localization at the centrosome depends on its N-
terminal domain and the presence of microtubules, while the C-terminal domain acts 

















Figure 1.10: Cellular localization of Aurora A and B in mitotic cells. Aurora A and B indicated as green 
box and red circle during different stages of cell cycle. The figure is adapted with permission 
(Carmena and Earnshaw) [90]. 
 
During maturation, the centrosome recruits various proteins to become completely 
active. Aurora A plays an important role here by phosphorylating TACC (transforming 
acidic coiled coil) which locates to the centrosome and interacts with microtubule-
associated protein (MAP) Msps/ch-TOG that promotes the growth of MTs [98, 99]. 
When Aurora is not present in the process, the mass of microtubule spindles is 
reduced about 60% and centrosome fails to recruit other proteins [95, 100]. 
Aurora A also plays a role in mitotic spindle assembly. Roghi and co-worker studied 
Xenopus egg extract and discovered the Ran-TPX2 pathway. Ran-GTP is a small GTPase 
that is needed for nuclear envelope assembly, mitotic spindle assembly and nuclear 
transport [101-103]. Usually, TPX2 is present in a complex, bound to importin α or β; 
it is released upon Ran-GTPase gradient formation, and then binds to Aurora A. TPX2 
binding activates Aurora A (Figure 1.11). RNAi studies show that depletion of TPX2 
cause less compact and multiples spindles, showing the importance of TPX2 for 
















Figure 1.11: Aurora A activity is regulated by TPX2 and Ran-GTP. TPX2 is associated as a complex with 
importins α or β. The release of TPX2 from complex occur by a gradient of Ran-GTP and 
subsequently binds to Aurora A. The figure has been adapted (Carmena and Earnshaw) [90]. 
 
As described above, TPX2 (Targeting Protein for Xenopus kinesin-like protein 2) is a 
microtubule-binding protein which plays a significant role in regulating the localization 
and the activities of Aurora A.  TPX2 is a substrate for Aurora A, but it was first found 
as a substrate for Xklp2 (Xenopus kinesin-like protein 2) [106, 107] . After release of 
TPX2 from importin α and β by Ran-GTPase, TPX2 binds to Aurora A which is activated 
and phosphorylates TPX2 [102, 108, 109].  The binding mechanism of TPX2 with 
Aurora A was revealed by biochemical and structural studies which gave more insight 
of their mutual cooperativity. TPX2 interacts with Aurora A with the N-terminal domain, 
similar to the binding of the hydrophobic motif in AGC kinases. Binding similarly 
activates the kinase, in part due to interactions with helix C, and also protects it from 
dephosphorylation by PP1 [110]. 
Toru Hirota and co-workers discovered another Aurora A binding partner called Ajuba. 
Ajuba is Aurora A specific, and does not activate Aurora kinase B. Ajuba is a lim protein 
which interacts with Aurora A in the mitotic cells and activates them by inducing 
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autophosphorylation on Thr288 residue. This was shown by a mutant of Ajuba and 
the absence of Thr288 phosphorylation in vitro, along with a lack of Aurora A kinase 
activity in the late G2 phase when the Ajuba level is depleted [111]. 
Bora is an approximately 64 kDa protein which is conserved from C. elegans to humans 
[112, 113]. Bora is a nuclear protein but it is translocated to the cytoplasm in a Cdc2- 
dependent manner, where they activate Aurora A (Figure 1.12).  Andrea Hutterer and 
co-workers showed that Bora increases Aurora A kinase activity about 8 fold [113]. 
Overexpression of Bora can rescue a defective Aurora A mutant, which suggests Bora 
and Aurora A interact [95, 113]. Biochemical and mutational studies also indicate that 
Bora interacts with Aurora A through their N-terminal domains (65-247, residue); this 
domain is more conserved than other part of the Bora [113]. The Aurora kinase is no 
longer active in mitosis with bora mutants, further indicating that Aurora A is regulated 
















Figure 1.12: Mechanism of Aurora A activation by Bora in Cdc2 dependent manner from 





Aurora B is also a serine/threonine kinase with roles in cell cycle regulation. James 
Bischoff and co-workers discovered Aurora B from a PCR-based screen [115]. Aurora 
B is the main component of the Chromosomal Passenger Complex (CPC), along with 
inner centromere protein (INCENP), survivin and borealin. Aurora B plays a role to 
synchronize chromosome condensation, segregation kinetochore function, spindle-
assembly checkpoint and cytokinesis [90, 116].  During mitosis, Aurora B is mostly 
active and its expression level approaches maximum at the G2-M transition [115]. The 
localization of Aurora B is maintained in prophase, prometaphase, metaphase and 
anaphase. Moreover, during metaphase the association of Aurora B in the 
centromeres is dynamic, as they exchange with proteins in the neighboring 
cytoplasmic pool [116, 117]. The regulation and localization of Aurora B are 
modulated by phosphorylation and their interactions with other proteins, such as 
INCENP, whose binding increases its kinase activity and help to locate to the 
centromeres in mitosis [118].  Aurora B localization and activity is also modulated by 
sumoylation.  The Small Ubiquitin-like Modifiers (SUMO) are a group of small proteins 
which act by attaching covalently to the target protein. The importance of sumoylation 
in the mitotic cellular process is evident in the kinetochore, centromere function and 
CPC complex [119-127]. The Aurora B kinase domain contains a conserved SUMO 
motif (ψ- Lys-x-Glu, in which ψ is a hydrophobic residue and x, any residue); the 
possible interaction occurs through covalent attachment at the lysine residue (K207). 
Biochemical and mutational studies indicate abnormal chromosome segregation and 
decreased cell viability when sumoylation is disrupted. Intriguingly, a K207R mutation 
of Aurora B does not show reduced kinase activity but the probable changes in 
localization [128]. The function of Aurora B is also modulated by acetylation.  
Acetylation at lysine215 (K215) of Aurora B by TIPO promotes its activity at 
kinetochores, chromosome bi-orientation. Acetylation also protects Aurora B 
activation from the phosphatase PP2A mediated dephosphorylation [129]. 
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As mentioned above, Aurora B is regulated by phosphorylation-dependent manner 
along with interacting other proteins, including INCENP. This is a microtubule-binding 
protein that serves as a positive regulator and substrate for Aurora B [130, 131].  The 
C-terminal of INCENP binds to the Aurora B and is phosphorylated by the kinase at 
two conserved serine residues; this generates fullly active kinase [131, 132] (Figure 
1.13). Survivin is a member of CPC which forms potential Aurora B substrates.  Aurora 
B phosphorylates the C-terminus of human survivin at threonine117. Biochemical 
data indicates that Aurora B mediates phosphorylation of survivin and regulates its 
activity. Survivin also binds another passenger of CPC [133, 134]. Borealin is a 31-kD 
protein which is a part of CPC, first discovered through proteomic screens. It is 
conserved in all vertebrates. Borealin binds INCENP and Survivin in vitro [135]. 
Borealin localization depends on other CPC member and RNAi studies show delayed 
mitotic progression and incorrect kinetochore-spindle assembly when it is depleted 
[135]. Borealin is phosphorylated by Aurora B and acts as a substrate. Co-expression 
of Borealin with other passenger members did not change the kinase activity [135].  
Aurora B also interacts with heat-shock protein 70 (HSP70). HSP70 protein is usually 
present in the cytoplasm, but methylated HSP70 (Lys561) observed in the nucleus of 
cancer cells. Hyun-Soo Cho and co-workers show that methylated HSP70 directly 






















Figure 1.13: Aurora B and chromosomal passenger complex.  a) Interactions of Aurora B, INCENP, 
Borealin, and Survivin. The N-terminus of Aurora B binds to the IN box of INCENP whereas Survivin 
and borealin interact with the N-terminus of INCENP. b & c) INCENP activates Aurora B by two-step 
activation. At first, INCENP partially activates Aurora B which autophosphorylated in the activation 
loop and another phosphorylation at the TSS motif in the C-terminus of INCENP increase kinase 
activity. The figure is adapted with permission (Ruchaud, Carmena and Earnshaw) [137]. 
 
1.2.3.5. Structures of Aurora kinases 
Aurora kinases have three domains: an N-terminal domain that is variable in length 
(39-129 amino acid residues), a catalytic kinase domain and a small C-terminal tail. 
The Aurora kinase catalytic domain presents the typical bilobal kinase fold, comprised 
of an N-terminal β-strand lobe and a C-terminal α-helical lobe, linked by a segment 
that acts as a hinge, about which the two lobes can rotate somewhat with respect to 
one another. The ATP binding site is in the interface between the two lobes. The ATP 
interaction is achieved via hydrogen bonds from the adenine moiety to the hinge, 
contacts from the ribose ring and the initial portion of the C-terminal lobe, 
coordination of the triphosphate by two metal cations bound by residues on the DGF 
motif (activation loop or T-loop) and catalytic loop (HRD motif), and triphosphate polar 
interactions with residues within the glycine-rich loop (G-loop). 
The Aurora kinase activity depends on regulatory mechanisms which include a toggle 
between active and inactive conformations via changes of orientation on the 
activation loop upon phosphorylation (Thr288 in Aurora A) together with changes in 
the orientation of the C-helix. A cognate of the so-called "PIF-pocket", which is located 
on the back of the N-terminal lobe, is also involved in the regulation Auroras, like the 
closely related AGC kinases. The Aurora consensus phosphorylation site is identified 
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as [KR]X[TS][ILV] [138], with Aurora B and C being less strict than Aurora A with respect 
to the hydrophobic residues.   
The first crystal structure of Aurora A was solved at 2.9 Å by Graham and co-worker 
in 2002 [139]. The following year, Richard Bayliss and his group determined a 
phosphorylated (T287, T288) Aurora A kinase structure with binding partner TPX2 
[110] . The complex structure revealed how TPX2 (1-43) binds at two distinct sites 
(Figure 1.14), the upstream segment TPX2 (residue 7-21) binds at the back of N-lobe 
and the downstream TPX2 (residue 30-43) binds in the αC helix between N and C-
lobe of Aurora A kinase [110]. Both segments of TPX2 engaged main and side chain 
atoms of Aurora A, most notably, Tyr8,10 and Ala12 of upstream TPX2 established 
interactions in the hydrophobic groove between the β sheet, helix αB and helix αC. 
The conserved tyrosine residues 8 and 10 from TPX2 show aromatic interactions with 
Tyr199 of Aurora A and cation-pi interactions with Lys166 and Arg179. Additionally, 
hydrophobic interactions between upstream TPX2 and Leu169, 178, Val182, Tyr199 
and Val206 of Aurora A are observed. The downstream part of TPX2 also exhibits 
interaction with Aurora A. The TPX2 bound Aurora A shows a typical active kinase 
conformation, like other AGC kinase active conformations [110]. Nevertheless, 
comparison of monomeric and TPX2 bound Aurora A structures show differences. 
The most prominent difference is in the activation loop where Thr 288 is exposed to 
solvent in the absence of TPX2 but interacts with Arg255 in the presence of TPX2 
bound Aurora A [110]. The phosphorylated [110] and unphosphorylated [139] 
structures adopt different conformation. The unphosphorylated structure shows a 
closed conformation [139]. The phosphorylated Aurora A has well-ordered activation 
segment [110]. The conserved Lys162 (β-3) aligns with phosphate, and Asp274 from 
the DFG motif coordinates a magnesium ion, while the catalytic base Asp256 is poised 
to transfer γ phosphate from ATP to substrates. The salt bridge interaction between 
















The structures of Aurora B kinase domain with INCENP from Xenopus laevis and Homo 
sapiens have been solved.  Both structures (Aurora B: INCENP) were solved in the 
presence of inhibitor, hesperidin in the Xenopus and VX-680 in the human Aurora B, 
respectively  [131, 140]. The Aurora B: INCENP and Aurora A: TPX2 complex structures 
are different from TPX2, as INCENP lines the N-lobe of Aurora B kinase on the side 















Figure 1.15: Aurora B kinase domain with Incenp 790–847 (PDB code: 2BFX). The Kinase 
domain of Aurora B represent here as purple -blue, INCENP as aqua-marine, Helix C as 
green, activation loop as red, phosphorylated Thr as yellow stick, Glu residue in the exit of 
hinge as white gray and glycine-rich loop as orange. 
Figure 1.14: The structure of Aurora A-TPX2 complex (PDB code: 1OL5). Aurora A represents 




Human Aurora B: INCENP was dimeric and resulted in the domain swap of the 
activation loop. Additionally, the DFG motif was found in a different conformation with 
VX-680, also in comparison to other kinase complexes [140-143]. The binding 
mechanism of INCENP is based on interactions with Aurora B in two sites called “site 
1” and “site 2”. The N-terminal part of INCENP (residues 842-863) interacts through 
site 1 and the pattern of interaction is almost similar to X. laevis Aurora B: INCENP 
structure, except for nonconserved interactions with Ile856 of INCENP and Leu210 of 
Aurora B (which match Arg812 and Tyr228 in X. laevis). The C-terminus of INCENP 
(residues 868-881) interacting at site 2 and the αC helix of Aurora B are displaced and 
the INCENP backbone shows a different conformation [140]. The salt bridge 
interaction between Lys122-Glu141 (the equivalent to Lys162-Glu182 in Aurora A) is 
suppressed. 
1.2.3.6. Aurora kinases and cancer 
The overexpression of Aurora kinases is observed in many tumor samples, such as, 
breast, colon, pancreatic, ovarian and gastric cells [115, 144-149]. The deregulated 
activity of Aurora kinases is tumorigenic and thus, Aurora kinases are considered as 
an important drug targets for cancer therapy. 
Systematic analyses of mRNA expression levels of Aurora kinases from different 
stages of primary tumour samples often revealed Aurora A and B overexpression 
[150]. TPX2, a partner protein of Aurora A, is also overexpressed in many tumor types. 
Their co-overexpression is frequent, indicating the existence of a novel functional unit 
with oncogenic properties [151].  
Aurora A regulates breast cancer-associated gene1 (BRCA1) by phosphorylation at  
Ser308 [152]. It is also modulates the inhibition of centrosome function by decreasing 
E3 ubiquitin ligase activity of BRCA1 [153].  Aurora A and Aurora B genes are 
upregulated by Myc in vitro and in vivo and maintain Myc-driven lymphoma [154]. 
William Clay and his co-workers developed a class of inhibitors that disrupts the native 
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conformation of Aurora A and consequently destabilizes the Aurora A and Myc 
interaction [155]. 
1.2.4. Targeting Aurora kinase 
The frequent overexpression of Aurora in many tumour cells put it in focus as a cancer 
drug target [115]. However, adequate specificity and selectivity has been difficult to 
achieve with recent methods of small-molecule kinase inhibitors design. The 
sequence and structure of highly conserved kinase domain, making the task is 
challenging to gain inhibitor specificity. In addition, the inhibitors should ideally target 
only cancer cells, as Aurora is important also in healthy cells, particularly for cell 
division. 
As mentioned earlier, Aurora A and Aurora B both play key roles in cell division, but 
the two Auroras act separately in time and space. Thus, the relative selectivity of 
inhibitors will be a key determinant of their therapeutic profiles. The kinase domain of 
Aurora A and B share 76% sequence identity (Figure 1.16) and only three amino acids 
differ from twenty-six residues in the ATP binding site. These are Leu215, Thr217 and 
Arg220 in human Aurora A, corresponding to Arg175, Glu177 and Lys164 in human 
Aurora B.  
Biochemical studies suggest that the amino acid residue Thr217 can play a key role 
in selectivity for Aurora A [160-163]. Vassilios Bavetsias and his co-worker mutated 
Thr217 into glutamic acid (as in Aurora B) and revealed that the compounds (28c and 
40f) were less sensitive to the mutant compared to wild-type Aurora A [156]. 
Moreover, introducing Ala, Gly, Ser, or Cys, at this position, does not affect inhibitor 
binding, but replacing it with a negatively charge residue prevents Aurora A inhibition 
[157]. Most of the Aurora A specific inhibitors were developed to exploit the Thr217 
sequence difference[158-161]. There are other features that distinguish Aurora 
kinases from other kinases, such as small gatekeeper Leu210, compared e.g. to CDK2 




























Goood understanding of protein-ligand interactions is crucial in the drug discovery 
process. The protein-ligand binding affinities is measured and described by the 
binding constant Ki (Eq. 1.). 
Ki = [ligand] X [protein] / [ligand--protein]  (1) 
Ki has the dimensions of a concentration usually the units of mol/L (M) and the binding 
constant is often determined by an enzymatic assay.  
Protein-ligand complex formation occurs most generally through non-covalent 
interactions. Hydrogen bonds (H-bonds) are the strongest and are typically the most 
critical for recognition, i.e. selectivity [162-164]. Typical hydrogen bonds can be 
grouped by the donor-acceptor distance and defined as; very strong (1.2-1.5 Å), 
Figure 1.16: Multiple sequence alignment of Aurora and PKA kinases (AUA, AUB, AUC 
and PKA represents as Aurora A, Aurora B, Aurora C and Protein Kinase A, 




strong (1.5-2.2 Å), moderate (2.2-3.2 Å), and weak (3.2-4.0Å), respectively [165]. 
Analysis of the 233 crystal structures of kinases revealed in addition to strong N–H···O, 
O–H···O, N–H···N hydrogen bonds, weak ones such as C–H···O, C–H···N that may be 
important [166]. Ionic interactions occur when the charged group of the ligand 
interacts with the oppositely charged group in the protein, forming so-called salt 
bridges when there are separated from one another by a distance between 2.7-3.0 Å 
[167], but the complementary charges also have a long-range energetic effect. 
Hydrophobic interactions are also observed in protein-ligand binding.  The interaction 
between lipophilic groups of ligand and non-polar amino acids of protein are 
attractive, directly via dispersion forces, but more importantly via the displacement of 
poorly bound water molecules at the surfaces of the uncomplexed molecules [167]. 
Other interactions are energetically important, such as pi-pi interactions, cation-pi 
interactions and metal complexation. For example, Gallivan and Dougherty showed 
that arginine was more prone to participate in cation-pi interaction than lysine by 
analyzing high resolution structures. They conclude the preference of aromatic side 
chains in cation-pi interactions to be Trp > Tyr > Phe [168].  
1.3.2. Strategies of kinase inhibitor design and current status 
The design of selective and specific kinase inhibitors is a major challenge due to the 
high sequence similarities of so many kinase domains. There have been many 
approaches used to discover selective kinase inhibitors, and three classes have 
emerged: Type I, Type II, and Type III [169-171].  
Type I inhibitors most closely mimic ATP, form hydrogen bonds (typically 1-3 hydrogen 
bonds) to the hinge region [172], and are ATP competitive inhibitors. Their  
hydrophobic interactions with the kinase have been systematically mapped [172, 
173]. The interaction region of Type I molecules can be divided into hydrophobic 
regions I and II, the adenine region, the ribose region and the phosphate-binding 
region [173] (Figure 1.17 & 1.18). Some of the known type I kinase inhibitors are as 
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follows; Vx-680 [174], MK-5108 [175], dasatinib [169], sunitinib [176] erlotinib [177] 














Figure 1.17: ATP binding site grouped into various region of kinase. (Adapted from Liu and Gray, 
2006) [169]. 
Type II inhibitors bind to specific inactive forms of a protein kinase. They are ATP 
competitive and use the ATP binding cleft. Additionally, type II inhibitors use an 
adjacent hydrophobic pocket which is created by the conformational change of the 
activation loop known as “DFG-out”. The conformational changes involve the release 
of the phenylalanine of the “DFG segment, creating an additional hydrophobic pocket 
which is not available in the activated kinase. The amino acids at this site are less 
conserved than ATP site, and the DFG-out forms of kinases are more diverse. As a 
result, it is likely that Type II inhibitors are more selective compared to Type I [179-
183] . Imatinib, the first approved type II kinase inhibitor showed promising selectivity 
over closely related kinase SRC[182].  The inhibitors: imatinib [184], BIRB796 [185], 
sorafenib [186], AAL993[187], indole amide[188], anilinoquinazoline [179] and 4-

















Figure 1.18: Schematic representation of kinase inhibitors interaction sites and different binding 
modes. (Adapted from Susanne et.al.) [189]. 
 
Type III inhibitors do not target ATP binding site, rather the allosteric sites of the kinase 
domain, away from ATP pocket. Therefore, they are considered as non-ATP 
competitive. They are expected to be highly selective as targeting allosteric pockets 
[190-194]. Several type III inhibitors are developed in the kinase drug discovery 
process; notably, trametinib; a MEK kinase inhibitor [189], and MK-2206, an allosteric 














Many nucleotide binding proteins contain a cluster of glycine, as a special feature for 
this kind of protein family. For example, the motif GxxGxGx was found to bind 
mononucleotides, while GxGxxG, bound dinucleotides [196, 197]. The catalytic kinase 
domain of protein kinases encompasses the ‘glycine–rich loop’ formed between β1 
and β2 of the N-lobe. The glycine-rich loop (G-loop), with the conserved motif glycine-
x-glycine-x-aromatic-glycine (G50xG52xaG55, residues numbering according to PKA), 
covers the ATP binding site and plays an important role in the interaction of the 
adenine ring and phosphates [16]. The G-loop acts as a multifunctional structural 
element by engaging itself in the substrates recognition, nucleotide binding,  and 
regulation of enzymatic activity [198]. It is generally accepted that the G-loop is the 
key determinant of the nucleotide positioning. In PKA numbering, the extended 
consensus sequence of the G-loop is Y49-G50-X-G52-X-[F/Y]54-G55-X-V57. The first 
and second glycine of the loop (Gly50 and Gly52) are nearly without exception among 
protein kinases; the two glycine residues provide space for ribose and an oxygen of 
the β-phosphates, respectively [198]. In PKA, the amino acid residue Thr51 of the G-
loop, which is quite variable across the kinome, interacts with arginine residue of 
inhibitor peptide. This position is varied across serine/threonine and tyrosine kinases 
[199]. Val57 of the G-loop has hydrophobic interactions with the adenosine moiety 
[198]. The aromatic residue adjacent to third glycine is conserved across the kinome, 
either as tyrosine or phenylalanine. In PKA it is phenylalanine (F54), and is often 
involved in interaction with inhibitors.  
An exceptional pattern is observed in ABL kinases which have an extra glycine in the 
second residue position. It is the target for leukemia drug imatinib, which induces a 
conformational shift, and was the first type II inhibitor observed.  Moreover, ABL 
kinase has tyrosine as the G-loop aromatic residue, while PKA, Aurora, PKC, and PKB 
have phenylalanine. Another exceptional pattern is seen in atypical protein kinase C, 
which lacks the third glycine. The Aurora kinase inhibitor, VX680 induces conformation 
changes in both Abl and Aurora, but Aurora lacks the extra glycine of ABL. The 
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sequences of G-loop is GGGQYG, GKGKFG, GTGSFG, in ABL, Aurora, and PKA, 

























Figure 1.19:	a) The glycine rich loop motif GxGxxG for PKA, PKB, PKC, Aurora, Abl, and 
consensus sequences, with anomalies marked for PKCi and ABL1.		b) The distribution of 





Biological macromolecules are surrounded by water, a property which fundamentally 
influences their interactions. In order for ligands to bind in a cavity of the protein, 
water must either be displaced or mediate the interaction. Thus, water molecules are 
essential factors of protein-inhibitor binding [200-206], and binding affinities depends 
also on details of water interactions with the complexed and uncomplexed molecules 
[207, 208]. Although the ATP binding mechanisms of protein kinases are highly similar, 
variations in side chains also create variations in water structure. This provides 
another opportunity for kinase inhibitor selectivity, as has been studied also in other 
enzyme classes. For example, in thrombin, displacing a well-ordered structural water 
molecule from a hydrophobic pocket correlates with 40-fold increase in binding 
affinity [209]. An example of water-mediated hydrogen bonding as a selectivity 
determinant for protein kinases is described for the approved leukemia drug 
bosutinib [210].  Another example describes the variation of binding energies due to 














Water molecules are observed in the hinge region and ATP pocket of protein kinases. 
Aurora A has conserved water molecules in the different binding region in ATP site 













Figure 1.20: The catalytic domain of kinase is showing conserved water molecules in the areas of the 
binding site. The areas where water molecules are found areindicated as follows: The Gly-rich loop/P-
loop (green), hinge(violet), the entrance of ATP binding site (light green), catalytic loop(lilac), activation 
loop(purple), and aC-helix (yellow). Adapted from Barillari, C., et al. [212]. 
 
Caterina Barillari and co-workers analyzed the high-resolution crystal structures of 
171 protein kinases and showed that Aurora A has four conserved regions in the 
binding site where water molecules are present and nine conserved water molecules 
in Pim-1 kinase, both represent serine/threonine protein kinases. There were four 
conserved water molecule areas located in Aurora A: between the activation and αC-
helix, near the G-loop, at the hinge and at the entrance of the binding site (Figure 
1.21). The superposition of Aurora A structures with inhibitors show variations of 
water pattern due to diverse inhibitor scaffold and kinase conformations.  Intriguingly, 
water patterns different across the kinome despite high sequence similarity of ATP 
binding site [212, 213]. Structural water molecules have been used to obtain 
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selectivity and affinity for Auroras B and C over Aurora A, and also for CDK kinase 
[214]. Moreover, Aurora A-ADP structures show a water mediate interaction with 
purine ring and threonine residue (Thr 217) [214].  The inhibitor VX-680, a Pan-Aurora 
inhibitor, interacts with Aurora kinase A (PDB code: 3E5A) through conserved water 
in the activation loop and beneath the G-loop, constraining the inhibitor to similar 
interactions otherwise only in ribosomal protein S6 kinase B1(PDB code: 3WE4) and 
JAK3 kinase PDB code: 4QPS). These examples show how conserved structural water 










Figure 1.21: a) Superpositions of Aurora A crystal structures has found the presence of conserved 
water molecules, b) Four conserved water molecules found in Aurora A (pdb code: 2J4z). The figure b 













Fragment-based drug discovery (FBDD) has become a common practice in the drug 
discovery process, and is routinely practiced to facilitate small molecule drug 
discovery. There are now some 30 drugs in clinical trials which originated from 
fragment-based approaches [215] (Table 1). A fragment is defined as a small organic 
molecule which generally follows the Rule of 3: molecular weight < 300Da, the number 
of hydrogen bond donors and acceptors ≤ 3, and ClogP < 3, as proposed by Astex 
researchers, and additionally the number of rotatable bonds is ≤ 3 and the polar 
surface area is ≤ 60 Å2 [216]. Fragments are low-molecular weight, low-affinity 
molecules which may later be developed into lead compounds by building them up 
employing medicinal chemistry knowledge and structure-activity relationships (SAR) 
for their target interactions. One specific approach is to link two fragments that are 
found to bind close to one another in the target protein binding cavity [217-219]. 
However, as fragments bind weakly to the target protein, it is often difficult to detect 
and measure their binding strength in conventional enzymatic assay techniques. 
These problems may be overcome by biophysical techniques such as X-ray 
crystallography, nuclear magnetic resonance spectroscopy(NMR), surface plasmon 
resonance, microscale thermophoresis (MST), differential scanning fluorimetry (DSF) 
and Isothermal titration calorimetry (ITC). X-ray crystallography, NMR and SPR are 
widely used methods in fragment screening, and newer methods are coming into use, 
such as mass-spectrometry, weak affinity chromatography and computational 
methods [217]. FBDD has been a well-known paradigm in protein kinase drug 
discovery; in fact, the first fragment-derived BRAF mutant kinase inhibitor is 
vemurafenib [220, 221] which was approved for the treatment of malignant 
melanoma. The progression started with an initial biochemical screening of 20,000 
low-molecular weight compounds (MW:150-350 Da), and 200 compounds resulted in 
inhibitory kinase activity against Pim-1, p38, and CSK [221]. Protein crystallography 
studied these fragments and explored the binding of 7-azaindole to the ATP pocket. 
Further optimization resulted in vemurafenib with activities against wild-type BRAF 
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and mutant with IC50 values of 160 and 13 nM, respectively [221]. The successful story 
of vemurafenib progression led other researchers to focus on FBDD approaches. 
There are many kinase inhibitors from FBDD approaches in clinical trials, including 
AT9283, pyrazole based inhibitor against Aurora kinases, JAK2 and Abl (T315I) [222] 
SNS-314, an Aurora kinase inhibitor developed from low uM to potent nM affinity 
[223], and SGX523, a MET kinase inhibitor [224]. An FBDD approach identified a 
fragment scaffold  (IC50 = 80 uM) against PKB which later was developed into high 
affinity inhibitor using rigorous analysis of SAR [225].  
FBDD provides opportunities to obtain new chemotypes for new inhibitors that may 
be derived from known inhibitors, such as AZD5363, which as a protein kinase B 
inhibitor, but a fragment of this inhibitor also showed inhibitory activity against RHO-
associated protein kinase 2 (ROCK2) [226, 227]. The progression of fragment-based 
drug discovery is not limited to kinases; it has been used widely in other target related 
proteins. The development of NVP-AUY922 [201, 228] and Onalespib inhibitor [229] 
against HSP90 has entered into clinical trials. FBDD has played a significant role in 
kinase inhibitor development; most of the fragment-based inhibitors now in clinical 
trials target protein kinases. However, there are still challenges to overcome for 
fragment-based drug discovery process, including the development of methods which 
detect fragment binding more efficiently, and better predictivity in structure based 












Table 1: Name of the FBDD drug which are in different stages of clinical phase[215]. 
Drug Name of the company Target Status 
Vemurafenib Plexxikon B-Raf (V600E) Approved 
Venetoclax AbbVie/Genentech Bcl-2 Approved 
PLX3397 Plexxikon FMS, KIT, and FLT-3-ITD Phase 3 
Verubecestat Merck BACE1 Phase 3 
AZD3293 AstraZeneca/Astex/Lilly BACE1 Phase 3 
AT7519 Astex CDK1, CDK2,CDK4,CDK5& CDK9 Phase 2 
AT9283 Astex Aurora & JAK2 Phase 2 
AZD5363 AstraZeneca/Astex/CR-
UK 
AKT Phase 2 
Erdafitinib Johnson & Johnson, 
Astex 
FGFR1-FGFR4 Phase 2 
Indeglitazar Plexxikon PPAR agonist Phase 2 
LY2886721 Lilly BACE1 Phase 2 
LY517717 Lilly/Protherics FXa Phase 2 
Navitoclax Abbott Bcl-2/Bcl-xL Phase 2 
NVP-AUY922 Vernalis/Novartis HSP90 Phase 2 
Onalespib Astex HSP90 Phase 2 
ABL001 Novartis BCR-ABL Phase 1 
ABT-518 Abbott MMP2 & MMP9 Phase 1 
ABT-737 Abbott Bcl-2 & Bcl-xL Phase 1 
ASTX600 Astex XIAP & cIAP1 Phase 1 
AT13148 Astex AKT, p70S6K & ROCK Phase 1 
AZD3839 AstraZeneca BACE1 Phase 1 
AZD5099 AstraZeneca Bacterial topoisomerase II Phase 1 
BCL201 Vernalis/Servier/Roche BCL-2 Phase 1 
DG-051 deCode Genetics LTA4H Phase 1 
IC-776 Lilly/ICOS LFA-1 Phase 1 
LP-261 Locus Tubulin Phase 1 
LY2811376 Lilly BACE1 Phase 1 
PF06650833 Pfizer IRAK4 Phase 1 
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PLX5568 Plexxikon RAF Phase 1 
SGX-393 SGX BCR-ABL Phase 1 
SGX-523 SGX Met Phase 1 





























The overall objective of this study was to use crystallography, experimental and 
theoretical biophysical tools, and surrogate kinases to investigate key structural and 
flexibility determinants of protein kinase ligand binding properties. 
Specific Objectives 
1) Investigate structural and dynamic features of the glycine-rich loop and inhibitors 
interactions. 
2) Studies presence of structural water molecules and their role in the kinase binding 
region. 





















Aurora A (residue 123-389) with N-terminal hexahistidine purification tag and TEV 
protease cleavage site was cloned into the vector, pNIC28-Bsa4 and expressed in 
E.coli (BL21(DE3)- pRARER) cells. There were few colonies used to inoculate 50 ml LB 
(Luria-Bertani) medium containing 50 μg/mL kanamycin and 34 μg/mL 
chloramphenicol and the cultures were grown overnight in a 250 mL flask at 37 °C 
with shaking 200 rpm. The following day, pre-cultures were transferred to large scale 
TB (Terrific Broth) medium (10 ml pre-cultures were added to 1L TB) containing 50 
μg/mL kanamycin and 34 μg/mL chloramphenicol into TB medium and grown at 37 
°C with shaking 200 rpm. When the OD600 of cells reached 0.5, the temperature 
reduced at 16 °C and Aurora A expression was induced at 0.8 (OD600) by adding 0.5 
mM isopropyl β-D-1-thiogalactopyranoside and left overnight. The Aurora A 
expressed cells were subsequently harvested by centrifugation at 6500 rpm for 25 
minutes and resuspended in binding buffer containing 50 mM Tris-HCl, pH 7.8, 400 
mM NaCl, 20mM imidazole,10% glycerol, 5mM β-mercaptoethanol and protease 
inhibitor cocktail (Roche). The resuspended cells were lysed using sonication and the 
lysate was centrifuged at 14500 rpm for 1 hour at 4°C. The supernatant was passed 
through nickel affinity HisTrap column and eluted with buffer containing 50 mM Tris-
HCl, pH 7.8, 400 mM NaCl, 500mM imidazole, 10% glycerol and 5mM 
mercaptoethanol. The hexahistidine tag was removed from the eluted protein using 
TEV protease overnight at 4 °C and subsequently, protein was pre-equilibrated in 
buffer 50mM Tris-HCl pH 7.5, 200mM NaCl, 10% glycerol and 5mM mercaptoethanol, 






The PKA variants, T51G, G55A, E127T, and T51G were made following a site-directed 
mutagenesis protocol [230]. The catalytic domain of PKA (wtPKA) and variants 
containing a N-terminal hexahistidine purification tag with a TEV protease cleavage 
site in the pET28-b vector was expressed in E.coli (BL21(DE3)- pRARER) cells using TB 
medium. The expression was carried out overnight at 17 °C by adding 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside when OD600 reached 0.8. The expressed cells 
were collected by centrifugation at 6500 rpm for 25 minutes and solubilized in binding 
buffer (binding buffer: 50 mM Tris-HCl 7.5, 300 mM NaCl, 20 mM imidazole and 
protease cocktail) and stored at -80 °C or -20 °C. The following day, the resuspended 
cells were lysed using sonication and the lysate was centrifuged at 14500 rpm for 1 
hour at 4 °C. The supernatant was filtered and protein was purified using a HisTrap 
column in affinity chromatography. After tag removal by TEV protease, the protein was 
purified using cation exchange chromatography using prepacked Resource S column. 
The column was equilibrated with 20mM K-phosphate, 20 mM KCl pH 6.5 and protein 
was eluted using a gradient from 20 mM to 500 mM KCl pH 6.5. The second cation 
exchange was done to get more homogeneity by changing pH 7.15 from 6.5 [231].  
The phosphorylation states were confirmed by MS-MS analysis. 
3.3. PKAB3 expression and purification 
The catalytic subunit of PKAB3 was expressed in the vector pT7-7 in E. coli BL21(DE3) 
RIL cells. The cultures were grown at 37 °C in 2YT media containing 100 μg/mL 
ampicillin and 34 μg/mL chloramphenicol and induced by at 0.7 (OD600) by adding 0.5 
mM isopropyl β-D-1-thiogalactopyranoside. The expressed cells were subsequently 
harvested by centrifugation at 6500 rpm for 25 minutes and resuspended in binding 
buffer containing 50 mM Tris-HCl pH 7.5 and 50mM NaCl. The resuspended cells were 
lysed using sonication and the cells debris removed by centrifugation at 14500 rpm 
for 1 hour at 4°C. The supernatant was adjusted by adding 5mM MgCl2 and 400 uM 
ATP as the final concentration which assured binding of PKA to the PKI mix Affi -gel 
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resin and kept for 4 hours at 4°C.  The PKAB3 supernatant purified by PKI mediated 
through gravity flow columns (PD-10 Columns, GE Healthcare) using 50 mM Tris-HCl 
pH 7.5, 2mM MgCl2, 400 uM ATP, 50 and 250 mM NaCl as washing buffer. Finally, the 
protein eluted with 200 mM L-arginine contained lysis buffer. Further, the 
phosphorylation states were purified cation exchange chromatography as described 
in wtPKA purification section. 
3.4. Kinase activity assay 
The activity of kinase variants was measured using NADH-coupled assay (Cook assay) 
and binding strengths of small molecule measured in an ATP-competitive manner 
[232]. Since protein kinase needed to transfer phosphate from ATP to respective 
substrates, Kemptide (LRRASLG) was used as a known substrate. The Cook assay was 
performed by adding kinase to the assay mixture (100 mM MOPS, pH 6.8, 100 mM 
KCl, 10 mM MgCl2, 1 mM phosphoenolpyruvate, 0.1 mM Kemtide, 1 mM β-
mercaptoethanol, 15 U/ml lactate dehydrogenase, 10 U/ml pyruvate kinase, and 0.21 
mM NADH). More than 10 dilution series of the small molecule in triplicates were used 
to the measured remaining activity of the kinase (decrease absorption of NADH) at 
340 nM using Molecular Devices “SpectraMax M2e” over a period of 10 minutes. 
Consequently, the inhibitory concentration at which the substrate conversion 
reduced 50 %(IC50) were calculated with GraphPad Prism 5 following dose-response-
function. Finally, the binding constant (Ki) was calculated using by Cheng and Prusoff 
equation [233]: 
                Ki = IC50/[1+([S]/KM, ATP)]   (3) 








The thermal shift assay was carried out by using a 4uM PKA-Au6 as a final 
concentration in 25 mM Bis-Tris HCl, pH 7.0, 150 mM KCl buffer, 10× Sypro Orange 
(Invitrogen). The final concentration of Maybridge fragments and inhibitors (AT9283 & 
NVP-TAE684) were 10 mM and 1mM, respectively. The experiments performed in 
quadruplicate, where 4% vol/vol DMSO used in the positive control and the negative 
control without DMSO, using Real-Time PCR detection system (BioRad) on Multiplate 
Low-Profile 48-Well Plates (BioRad). The samples were heated at 1°C per min, from 
10° C to 95° C. The data were analyzed with Opticon Monitor software (Bio-Rad) and 
the thermal shifts were calculated from subtracted control, ΔTm = Tsample – Tcontrol. 
 
3.6. Surface plasmon resonance (SPR) 
SPR binding studies were performed at 25 °C using a Biacore T200 (GE Healthcare).  
Aurora A, PKA-Au6, T51G PKA, and G55A PKA were diluted to 25 to 30 ug/mL in 10 
mM Bis-Tris pH 6.5 separately. The immobilization was carried out at 25 °C at a flow 
rate 30 uL/min using 10mM HEPES pH 7.4 with 150 mM NaCl. The proteins were 
covalently coupled to the S-series CM5 sensor chips (GE Healthcare) through 
standard NHS/EDC amine coupling. The amount of immobilized proteins was 
determined to a level between 5000 to 8000 RU. Interaction studies were started by 
injections of dilution series of inhibitors concentrations at a flow rate of 30 μL/min for 
the 60 seconds (association) and 600 seconds (dissociation) at 25 °C. The running 
buffer contained 20 mM HEPES pH 6.8, 150 mM NaCl, 2mM MgCl2, 0.05 % Tween and 
2% DMSO, respectively. The inhibitors were dissolved in 100 % DMSO and diluted 
such a way with running buffer (without DMSO) to keep DMSO level at 2% in the 
inhibitors dilution series. In the blank injections, running buffer was used and the bulk 
effects were adjusted using solvent correction. The unspecific binding was removed 
by subtracting SPR signals from a blank flow cell. After each cycle, the sensor chip was 
regenerated by injecting 100mM NaHCO3 pH 8.6. The kinetics data were analyzed 





PKA was crystallized at 4 °C in hanging drops.  The droplets contained 10 to 16 mg/ml 
protein with 25 mM Bis-Tris-HCl pH 7.0, 150 mM KCl, 1.5 mM octanoyl-N-
methylglucamide and 0.8 mM PKI peptide. The droplets were equilibrated against 12-
26 % (v/v) methanol and crystals appeared within a week. The crystals were soaked 
with ligand (1c, 1b,1e, 1i and 1p) as final concertation of 4mM overnight at 4 °C. PKA-
Au6 was crystalized in the same manner as wtPKA and crystals were soaked with 
inhibitor AT9283 as 4mM final concentration. The wtPKA:ARC-1416 complex was 
successfully crystallized in the conditions of 18% PEG3350, 0.2 M Li2SO4 at 4 °C. 
PKAB3 was co-crystalized with ligands (1c and 1p) at 4 °C in hanging drops. The drops 
contained 10 to 16 mg/mL protein, 1mM ligand with 25 mM Bis-Tris-HCl, pH 7.0, 150 
mM KCl, 1.5 mM octanoyl-N-methylglucamide and 0.8 mM PKI peptide and 
equilibrated against 12-26 % (v/v) methanol. All the crystals were frozen in 30-40 % 
MPD for data collection. 
3.8. X‐ray diffraction and structure determination 
The diffraction data of crystals were collected at the European Synchrotron Radiation 
Facility (ESRF, Grenoble, France) and at the 14.1 beamline at Berlin Electron Storage 
Ring Society for Synchrotron Radiation (BESSY, Berlin). The diffracted images were 
processed, integrated and scaled by using either XDS and XSCALE [234] or with 
MOSFILM [235]and SCALA [236]. Molecular replacement and structure refinement 
were done by MOLREP [237] , PHASER [238], REFMAC5 and Phenix [239]. The 
coordinate and molecular topology files for ligands were created with PRODRG [240] 






The structure-based design of kinase inhibitors have focused mostly on interactions 
with rigid regions of the kinase, in the hinge region with its surrounding ATP binding 
pockets. Flexible elements such as the glycine-rich loop have been recognized as 
important, but have not been the focus for optimization. Here, we studied a series of 
PKA and PKAB3 inhibitors using enzyme activity assay and determined their binding 
modes by protein crystallography. The inhibitors were designed and synthesized to 
study the ligand binding properties of the glycine-rich loop by incorporating different 
halogenated benzoyl or carbothienyl substituents along with the hinge region and 
ribose pocket. Kinase activity assays showed that most of the inhibitors have 
nanomolar binding affinity against PKA and PKAB3 (Paper I). The crystal structure of 
wtPKA with inhibitor (+)-1b is found interact to the Glu121 and Val123 in the hinge. 
The benzoyl C=O group of (+)-1b has contact with Gly50 from glycine-rich loop at a 
distance of 3.0 Å. Additional interactions are observed from residues Glu127, Glu170 
and Asn171, respectively. The side chain of Asp184 from the DFG loop also interacts 











 Figure 4.1: Binding mode of (+)-1b with wtPKA (PDB code: 4UJB). Color 




The Glu127, Asp184 interactions with the ribose pockets are predominant among 
AGC and CMAK families of kinases.  Only two tyrosine kinases, PTK2 and PTK2B, have 
similar interactions [241]. Glu127 is the key selectivity determinant that distinguishes 
Aurora kinase A from B; Aurora A has Thr217 and Aurora B has a glutamic acid residue 
in the similar position [156, 157].  
The crystal structure of PKAB3 with inhibitors (+)-1p (PDB code: 4Z83) revealed the 
conformational flip of the Met173 side chain. The Leu173 residue (Met173 in PKAB3) 
in PKA showed favorable interaction with quinazolinone ring (Figure 3, Paper I). Due 
to side chain flip of Met173 in PKAB3, the inhibitors interactions are less favorable 
which might have explained why all inhibitors were more potent against PKA than 
against PKAB3. Biochemical studies showed inhibitors with para-substituted phenyl 
and thienyl derivatives have higher affinities than meta-substituted derivatives. The 
crystal structure of PKA with the para-substituted inhibitor (with a F3C-phenyl ring) (+)-
1I (PDB code: 4UJ9) showed extensive interactions between the inhibitor and the 
glycine-rich loop (Figure 4.2). The binding affinities in para-substituted inhibitors 
(except (+)-1h) are stronger than meta-substituted inhibitors. (The inhibitor (+)-1h has 
fluorine as substituents which are small compared to rest.) The thiophene derivatives 
are tight binding (e.g. (+)-1n with Ki=170 nm) inhibitors, and the addition of halide in 
ortho-position to the sulfur atom of the thiophene substituent increases affinity ((+)-



















              Figure 4.2: Crystal structure of compound (+)-1l (a, PDB code: 4UJ9) and (+)-1p (b, PDB code: 
4UJA) bound to PKA. a).  The interaction of F3C-phenyl ring ((+)-1l) in to the glycine-rich loop. b) 
Interactions between the Br atom and the glycine-rich loop. Color code: ligand green; O red, N blue, F 
light blue, S yellow, Br dark red. Figures adapted (Lauber, B, et. al.) [242]. 
 
The adenosine analogue-oligoarginine conjugate ARC1416 is a bifunctional inhibitor 
that also interacts with wtPKA through hinge interactions combined with peptide 
binding site interactions, as shown by crystal structures (Paper IV). The inhibitor 
developed using 7-deazapurine as adenine moiety with α, ω-nonanedioicacid linker 
and five number of D-arginine residues were added to the target peptide binding site. 
Dynamic scanning fluorimetry showed ΔTm of 16.7 °C for wtPKA which is higher than 
previously reported PKA inhibitors [243], but 5 fold less sensitive for ATK3/PKBγ. The 
co-crystal structures revealed deazapurine to interact with Glu121, Val123 at 2.9 and 
3.8 Å, respectively. The D-Arg2 interacts with Glu127 at 3.2 Å (Figure 4.3).  The residue 
Glu127 interactions with inhibitor were also mentioned earlier. Moreover, The D-Arg4 

























Figure 4.3: The co-crystal structure of wtPKAc: ARC1416 (PDB code: 5J5X). ARC1416 interacts with 
wtPKA through hinge region and peptide binding site.  
 
4.2. Dynamic properties of ligand binding 
Protein kinases are very dynamic in nature and the glycine-rich loop represents one 
of the most flexible regions of protein kinase A. The amino acid residue Thr51 (PKA) 
of the glycine-rich loop interacts with arginine residues of inhibitor peptide. This 
position is typically either threonine or serine in serine/threonine or tyrosine kinases 
[199]. However, an exceptional pattern is observed in ABL kinase which has an extra 
glycine in the second residue position and is the target for leukemia drug imatinib, 
which induces a conformational shift in the shape of the glycine-rich loop. Another 
exception is seen in atypical protein kinase C, which lacks the third glycine. The Aurora 
kinase inhibitor VX680 is interesting as a cross-reactive inhibitor of ABL as well, and it 
induces conformation changes in the glycine-rich loops of both proteins. However, 
Aurora does not have the extra glycine of ABL. In order to study the dynamic 
properties of this loop, we have mutated residues of T51G and G55A in PKA (Paper  
II).  The enzymatic assays showed significant changes in their binding affinities (Ki) with 





* from Lauber et al.[242]. 
ǂ from Plug et.al.[244]. 
n.d.-not determined. 
 
The inhibitors have decreased affinities (Ki) against PKA mutants compared to wtPKA 
(Paper II). Investigating wtPKA-1l, 1p, crystal structure (PDB code: 4UJ9 & 4UJA, 
respectively) revealed an extended interaction network in the glycine-rich loop and 
peptide bond Thr51-Gly52 where the para-F3C –phenyl ring made multiple favorable 
contacts [242, 245, 246]. The loss of binding affinities is due to conformation changes. 
Replacement of threonine with glycine seems likely to facilitate conformational 
changes, and increase flexibility. The inhibitor 1c shows a 12 fold decrease in affinities 
with the G55A mutation, similar to H89.  Susan Taylor and co-workers [247] studied 
the three glycine sites via mutation to serine, showing an approximate 10 fold 
reduction of affinity for ATP for the first two sites. However, the third  glycine mutation 
G55S had no apparent affect on nucleotide binding [247]. To summarize results, we 
mutated T51G and G55A to the corresponding residue of ABL and PKC kinases, 
respectively. The affinity for ATP almost same (4-6 uM) for wtPKA and both mutants 
but there are dramatic shifts with respect to inhibitor binding energies. 
4.3. Water determinants of ligand binding 
Water molecules play an essential role in protein-ligand binding mechanisms [200-
207]. In order to bind the ligand to the cavity of the protein, water molecules need 
either be displaced or mediate the interaction.  As a consequence, the binding affinity 
depends on details of the water interactions [207, 208].  There is a water molecule 
Kinase 1l 1p  1c H89 
G55A 0.5 0.6  3.87 0.44 
T51G 0.09 1  n.d. n.d. 
WtPKA 0.002* 0.0009*  0.3* 0.063ǂ 
Table 2. Binding affinities (Ki) measured based on ATP competitive enzymatic assay and 
presented in uM.  
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(Paper I) present in the meta-aryl-substituted inhibitors 1c and1e complex with PKA 
close to Phe54 from the glycine-rich loop. Intriguingly, this water molecular is also 
present as a cluster in the eight of the thirteen PKA structures with similar loop 
conformation (Figure 4.4) [242].  For the para-substituted inhibitor 1l (Ki = 2 nM), the 
CF3 substituent displaced the water molecule and gained approximately 40 and 150-
fold binding affinities compared to 1c (Ki= 300 nM) and 1e (Ki= 80 nM) [242]. This is 
analogous to effects characterized for e.g. thrombin, where displacing a well-ordered 
structural water molecule from a hydrophobic pocket correlates increase binding 













The ATP binding mechanisms of the Aurora kinases are highly similar to the other 
protein kinases. As most approved protein kinase inhibitor drugs target ATP binding 
sites, adequate selectivity for target kinases has been demonstrated, but it remains a 
major challenge to achieve target specificity. The specificity of protein kinase inhibitors 
is of course determined by the amino acids surrounding the ATP sites (e.g. Thr217 in 
Aurora A vs Glu in Aurora B), but structural water molecules also play a key role. An 
example of water mediated hydrogen bonding as a selectivity determinant for protein 
Figure 4.4: Presence of water molecule in front of Phe54 in the presence of 
iodo-substituted inhibitor (PDB code: 4UJ2). 
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kinases is shown by the approved leukemia drug bosutinib [210] and it can play role 
in getting pharmacological selectivity [206].  Both effects, the role of conserved water 
molecules and the changes of single amino acid, contribute to affinity and specificity 
[211]. The conserved clusters of water molecules in Aurora A were identified by 
superimposing crystal structures (Paper V). There were 42 Aurora kinase A crystal 
structure used in this study (Figure 4.5). Aurora A structures with resolution better 















Figure 4.5: Clusters and scattered distribution of water molecules at the ATP binding pocket. Spheres 
with shades of red mark different clusters at or near a pocket found between ATP, the gate-keeper, 
and the aspartic acid of DFG. The figure has been taken with permission (O.A. Gani, et.al.) [213]. 
 
Rational drug design based on the targeted structural water molecules increase the 
ligand binding affinity [248]. Structural water molecules can be used for increasing 
ligand efficiency in Aurora kinase A.  
 
4.4. Kinase–ligand interactions studies using thermal shift assay 
Studies of protein kinases-ligand interactions are critical to improve drug discovery 
and design processes. The establishment of screening assays often require time and 
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are expensive as well. Sometimes the methods are not compatible to assess all kinds 
of inhibitors due to technique limitations. However, there are several techniques that 
are simple and inexpensive. Differential scanning fluorometry (thermal shift) is a 
popular, rapid, inexpensive and powerful technique to study protein ligand stability 
interactions, especially for low molecular weight compound like fragments [249, 250]. 
Thermal shift assays monitor the stabilization introduced by ligand binding to the 
protein which is measured in the presence and absence of inhibitors. The measured 
ΔTm values correlate with KD and IC50 values [249, 251]. In this study, we used a 
thermal shift assay to investigate Maybridge fragments, and known kinase inhibitors 






































Multitargeted kinase inhibitors AT9283 and NVP-TAE684 showed ΔTm 4.95 °C and 3.75 
°C, respectively. The crystal structure of PKA-Au6 with AT9283 complex revealed 
classical hinge hydrogen bond interactions with the pyrazole scaffold of the inhibitor. 
The glutamic acid (E121) and alanine (A123) formed three hydrogen bonds with 
AT9283 (Figure 4.9). Similar hinge-pyrazole interactions are observed in Aurora kinase 
A [222]. Thus, these interactions might be the cause of the higher ΔTm. Moreover, the 
known kinase inhibitors such as VX-680, staurosporine, sunitinib and JNJ-7706621 
have ΔTm values higher than 5 °C [249]. The binding affinities (Ki) of AT9283 and NVP-
TAE684 are measured based on an ATP competitive enzymatic assay against PKA-Au6. 
Both compounds show tighter binding and Ki values are 33 and 36 nM, respectively. 
The correlation of thermal shifts with Ki values indicate that Tm shifts > 4 °C likely 
represent binding affinities in nanomolar range (<1 uM) [243, 252]. 
The Maybridge fragments which were selected based on molecular docking were 
tested by the thermal shift assay. The fragments ligand_24 (ΔTm=2.7 °C) and ligand_35 
(ΔTm= 2.4 °C) resulted ΔTm > 2 °C. Only ligand_1868 (ΔTm=0.3 °C) showed ΔTm < 0.5 °C. 
Fragments which exhibited ΔTm > 0.5 °C can be used as a hit for further development 
[253].   
Figure 4.7: The thermal shift screen exhibited a varied range in ΔTm (from 0.3 to 5.0 °C) to 






Figure 4.8: X-ray structure of PKA-Au6 and Aurora A with AT9283. Analogously, 
AT9283 interacted in the in the hinge region of both kinases. PKA-Au6 is 
colored as cyan and Aurora A as gray. Only hinge region is shown here for 





Addressing the Glycine-Rich Loop of Protein Kinases by a Multi-Facetted Interaction 
Network: Inhibition of PKA and a PKB Mimic.   
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Protein kinase A is a prototype for protein kinase studies, including its use a kinase 
for other protein kinase targets. We described here the design, synthesis, and tests 
of a series of 32 enantiomerically pure inhibitors of protein kinase A (PKA) and its 
mutant PKAB3 as the mimic of PKB. The ligands bind to the hinge region, ribose 
pocket, and their substituted aromatic rings (phenyl, thienyl) target interactions with 
the glycine-rich loop at the ATP site of the proteins. Biological assays showed high 
potency against both PKA and PKAB3, with a preference for PKA. The crystal structures 
revealed a multi-facetted network of ligand–glycine-rich loop interactions, whereby 
efficient water replacement contributes to the binding strength. The results suggest 
that aromatic rings of the inhibitors with para-CF3-phenyl and 5 bromothienyl 
substituents are involved in arene interactions with optimzed interactions with the 
glycine-rich loop. The para-substituted or thiophene-substituted inhibitor weres 10-
100-fold more active that the meta-substituted compounds, because the meta-












Flexibility properties of the protein kinase glycine-rich loop are critical for inhibitor 
binding 
Kazi A. Alam, Osman A. B. S. M. Gani, Tony Christopeit, and Richard A. Engh. (Manuscript). 
 
 
The glycine-rich loop is the dynamic and flexible part of the kinase domain of protein 
kinases. The glycine-rich loop with the conserved motif glycine-x-glycine-x-aromatic-
glycine (G50xG52xaG55, residues numbering according to PKA), involved in 
interactions with the ATP binding site. The amino acid sequence of this motif is not 
strictly conserved across the kinome. An exceptional pattern is observed in ABL 
kinases which have an extra glycine in the second residue positions (GGGxxG), and in 
atypical PKC, which lacks the third glycine (GxGxxA). In this paper, we studied the 
effects of the inhibitor binding with corresponding mutations in the glycine-rich loop 
(T51G and G55A in PKA). We tested inhibitors against T51G and G55A. The binding 
affinities of 1i, 1p, 1c and H-89 is weakened by several orders of magnitude. The 
results revealed the higher sensitivity of the inhibitors which were developed to target 
the loop.  However, the binding of staurosporine, a pan-kinome inhibitor, is 
strengthened by both mutations. The increased affinities of staurosporine may be 
explained by the structural changes of the loop which resulted in faster association 




















Inhibitor induced structural effects involving Phe327 in AGC kinases. 
Kazi Asraful Alam, Ulli Rothweiler, Osman A. B. S. M. Gani, and Richard A. Engh. (Manuscript). 
 
Protein kinases are regulated in dynamic manner by interacting with various proteins, 
substrates and movement of domains or motifs. As such, the C-terminal stand (C-tail) 
of AGC kinases also regulates its kinase activity. In this work, we show the highly 
conserved aromatic residue phenylalanine (Phe327 in PKA) in AGC kinases and its role 
in kinase-inhibitor binding. The inhibitor-Phe327 interactions showed complex 
behavior. Phe327 can block inhibitors from occupying the ATP-binding pocket, or may 
be moved to enable good binding interactions. The PKA-based Aurora kinase (PKA-
Au6) model which has Phe327 show the displacement of this residue in crystal 
structures (PDB ID: 5N23) and its affects on binding affinities of pan-aurora inhibitor 
AT9283.  Binding studies of tricyclic dianilino-pyrimidine scaffold based 1B and 2A 
show the former inhibitor exhibit more potent against PKA-Au6 while the latter 
inhibitor is more effective against to Aurora A. The weaker affinity of 2A is might be 
effects from Phe327.  Similarly, Barasertib is a potent Aurora B inhibitor with weaker 
binding affinity to the PKA based model. Inhibitors induced displacement was 
















Bifunctional Ligands for Inhibition of Tight-Binding Protein–Protein Interactions. 
Bioconjugate Chem., 2016, 27 (8), pp 1900–1910. DOI: 10.1021/acs.bioconjchem.6b00293. 
Taavi Ivan, Erki Enkvist, Birgit Viira, Ganesh babu Manoharan, Gerda Raidaru, Alexander Pflug, Kazi 
Asraful Alam, Manuela Zaccolo, Richard Alan Engh, and Asko Uri. 
 
Bifunctional or bisubstrate ligands can be used for studies of strong protein peptide 
interactions. In this work, we report adenosine analogue-oligoarginine derivatives ARC 
14108, 1411 and 1416 inhibitors interaction against the catalytic subunit of wtPKA.  
Biophysical studies revealed 7-deazapurine as a tight binding nucleotide moiety with 
the addition of linker.  The number of d arginine residue increase in ARC1416 based 
on 1409 (1000-fold higher affinity toward PKAcα). The co-crystal structures show 
interactions with hinge and peptide binding region including different glycine-rich 
loop refolding configurations. The bifunctional ligand Arc1411 disrupted tight binding 
tetrameric holoenzyme of cAMP-dependent protein kinase (PKA) whereas the ATP site 
inhibitor H89 was not able to dissociate them. Thus, these studies show a new route 
to develop inhibitors for protein protein interactions which may be used as an 














Assessing protein kinase target similarity: Comparing sequence, structure, and 
cheminformatics approaches. 
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. Volume 1854, Issue 10, Part B, October 
2015, Pages 1605–1616. 
Gani, Osman A.B.S.M.; Thakkar, Balmukund; Narayanan, Dilip; Alam, Kazi Asraful; Kyomuhendo, Peter; 
Rothweiler, Ulli; Tello-Franco, Veronica; Engh, Richard Alan. 
 
Although protein crystallography provides us atomic resolution data which shows 
protein ligand interactions in great detail; the energies of ligand binding cannot be 
predicted precisely from individual structures. However, the availability of kinase 
inhibitors structures along with biophysical results enable statistical methods to 
assess similarity and identify key factors. In this paper, we have analyzed kinase target 
similarity by sequence, structure, and binding data. Examples of the gatekeeper and 
“gatekeeper +2” residues distribution provide examples of specific selectivity 
determinants. Statistical measures based on residue identities and also inhibition 
profiles identify similarities between targets. These measures are only statistical, 
however. For example, Aurora and ABL kinases are quite distinct, but share tight 
binding with VX680. Statistical measures also identify clusters of conserved water 
positions. The superpositions provide information regarding the importance of the 













On methionine as a gatekeeper residue for protein kinase inhibition targets. 
	
Dilip Narayanan, Kazi A. Alam, Matthias M. Engh, Richard A. Engh, Osman A.B.S.M Gani. (Manuscript). 
 
The gatekeeper residue in kinase domain of protein kinases acts as an important 
selectivity determinant for kinase inhibitor interactions. Methionine is the most 
frequent gatekeeper residue in protein kinases; approximately 40% of the gatekeeper 
residues are methionine in the human kinome. EGFR has threonine, however, and the 
mutation of this gatekeeper residue to methionine creates drug resistance. 
Methionine side chain interactions, especially the sulfur interactions are interesting 
for their contributions to the binding affinity. In this paper, we show the side chain 
and rotamer distribution of methionine and their inhibitor binding pattern using 
available structures and binding data from different databases. We choose PKA as a 
model for study as it has methionine as a gatekeeper residue. We screen fragments 
from an in-house library by using molecular modeling and solve the crystal structures 
of two fragment (Frag195_Cl and Frag 414_S) complexes in PKA. The structures reveal 
different methionine rotamer conformations in Frag195_Cl and for Frag414_S, the 
structure is flipped by 180 about an axis perpendicular to the ring. These studies 
should aid the design of new protein kinase inhibitors against gatekeeper Met protein 










Protein kinase A, surrogate kinase, and Aurora kinase A were used to study kinase 
inhibitor binding mechanisms. Several biophysical techniques were applied to 
investigate kinase-ligand interactions in dynamic and atomic level. Ligands were 
designed and synthesized to targeting the ATP binding site and in particular the 
glycine-rich loop of PKA and PKB. Although known to be important, this loop has not 
generally been addressed specifically before in most protein kinase inhibitor design 
programs. Crystal structures with inhibitors revealed details of their binding modes 
and showed that the ligand interactions with the glycine-rich loop enhanced binding 
affinities. Biophysical characterization of the glycine–rich loop mutants (T51G and 
G55A) showed weaker affinities against the inhibitors which have interactions with the 
loop. Structural and biochemical studies of glycine-rich loop addressed inhibitor 
considered the loop is a hot spot for developing kinase inhibitors. However, further 
work is needed to test these inhibitors against native PKB if that is the best target, 
which may lead to better understanding of the energetics of glycine-rich loop 
interactions. The co-crystal structures of wtPKA with bisubstrate inhibitors showed 
differences in glycine-rich loop conformations. The bisubstrate approach targets dual 
sites of both ATP and substrate binding, enabling high specificity and the disruption 
of tight-binding protein complexes.  
PKA-Au6 (Aurora B model) was used to study selectivity determinants. Different 
inhibitors tested showed the residue Phe327 of PKA-Au6 to play a significant role in 
inhibitor selectivity, for example either by accommodating or blocking inhibitors in the 
pocket.  Tricyclic dianilinopyrimidine compounds (1B & 2A) showed intriguing results 
where 1B is selective against PKA-Au6 but 2A was weakened binding affinities, like 
Barasertib. Structural analysis of these inhibitors with PKA-Au6 model suggests that 
there might be a clash between the side chain of Phe327 and inhibitors (2A & 
Barasertib). However, additional studies required to make such a statement. 
63 
 
Analysis of Aurora A crystal structures demonstrated the presence of structural water 
molecules in the different region of ATP binding pocket. Water replacement by the 
ligand in the loop region contributes to the binding strength and careful examination 
facilitates the design of better selectivity among kinases. Fragment-based approach 
aids to find new scaffold and novel kinase inhibitors. PKA-Au6 was also used for the 
studies of the fragments. The fragments named ligand_24 (ΔTm=2.7 °C) and ligand_35 
(ΔTm= 2.4 °C) show ΔTm > 2 °C which indicates the possibility of the fragments to 
develop as inhibitors. The crystal structures of two fragment (Frag195_Cl and Frag 
414_S) complexes in wtPKA revealed different methionine rotamer conformations. 
PKA has methionine as a gatekeeper residue. The abundances of methionine in the 
gatekeeper position are high in the protein kinases; and methionine side chain 
interactions, especially the sulfur interactions are interesting for their contributions to 
the binding affinity. In sum, these studies provide a range of information that can aid 
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